NeuroPace Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $18.124M Beat $17.302M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeuroPace (NASDAQ:NPCE) reported Q1 2024 earnings with a smaller loss per share of $(0.32) compared to the $(0.33) estimate and a 21.95% improvement from last year. Sales reached $18.124M, surpassing the $17.302M estimate and marking a 25.23% increase from the previous year.
May 08, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroPace reported a smaller-than-expected Q1 2024 loss and higher sales, indicating strong performance and growth.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can drive the stock price up in the short term. The significant improvement in performance compared to the same period last year further strengthens the case for a positive impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100